Librería: ThriftBooks-Dallas, Dallas, TX, Estados Unidos de America
EUR 41,70
Cantidad disponible: 1 disponibles
Añadir al carritoHardcover. Condición: As New. No Jacket. Pages are clean and are not marred by notes or folds of any kind. ~ ThriftBooks: Read More, Spend Less.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 49,49
Cantidad disponible: 1 disponibles
Añadir al carritoCondición: New.
Librería: PBShop.store US, Wood Dale, IL, Estados Unidos de America
EUR 52,66
Cantidad disponible: 2 disponibles
Añadir al carritoHRD. Condición: New. New Book. Shipped from UK. Established seller since 2000.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 50,95
Cantidad disponible: 1 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
EUR 48,10
Cantidad disponible: 2 disponibles
Añadir al carritoHRD. Condición: New. New Book. Shipped from UK. Established seller since 2000.
Idioma: Inglés
Publicado por Taylor and Francis Inc, US, 2019
ISBN 10: 1498761305 ISBN 13: 9781498761307
Librería: Rarewaves.com USA, London, LONDO, Reino Unido
EUR 56,50
Cantidad disponible: 1 disponibles
Añadir al carritoHardback. Condición: New. Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization.Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.
Idioma: Inglés
Publicado por Taylor & Francis Inc, Portland, 2019
ISBN 10: 1498761305 ISBN 13: 9781498761307
Librería: Grand Eagle Retail, Bensenville, IL, Estados Unidos de America
EUR 57,59
Cantidad disponible: 1 disponibles
Añadir al carritoHardcover. Condición: new. Hardcover. Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersitys Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization.Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission. The first book on the design and analysis of not only clinical trials but also how observational non-interventional data using clinical data is applied to economic evaluation and re-imbursement in the context of Cancer. This book is a non technical exposition of economic evaluation and no knowledge of advanced statistical methods is assumed. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.
Idioma: Inglés
Publicado por Taylor and Francis Inc, US, 2019
ISBN 10: 1498761305 ISBN 13: 9781498761307
Librería: Rarewaves USA, OSWEGO, IL, Estados Unidos de America
EUR 57,77
Cantidad disponible: 1 disponibles
Añadir al carritoHardback. Condición: New. Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions. Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization.Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.
Librería: Ria Christie Collections, Uxbridge, Reino Unido
EUR 47,68
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. In.
Idioma: Inglés
Publicado por Chapman and Hall/CRC 2019-06-28, 2019
ISBN 10: 1498761305 ISBN 13: 9781498761307
Librería: Chiron Media, Wallingford, Reino Unido
EUR 44,12
Cantidad disponible: 2 disponibles
Añadir al carritoHardcover. Condición: New.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 47,07
Cantidad disponible: 2 disponibles
Añadir al carritoCondición: New.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 64,02
Cantidad disponible: 10 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 66,38
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 52,09
Cantidad disponible: 2 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 71,32
Cantidad disponible: 10 disponibles
Añadir al carritoCondición: New.
Librería: California Books, Miami, FL, Estados Unidos de America
EUR 73,68
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: Majestic Books, Hounslow, Reino Unido
EUR 67,63
Cantidad disponible: 3 disponibles
Añadir al carritoCondición: New.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 73,25
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: Majestic Books, Hounslow, Reino Unido
EUR 67,86
Cantidad disponible: 3 disponibles
Añadir al carritoCondición: New.
Librería: THE SAINT BOOKSTORE, Southport, Reino Unido
EUR 53,26
Cantidad disponible: 2 disponibles
Añadir al carritoHardback. Condición: New. New copy - Usually dispatched within 3 working days.
Librería: HPB-Red, Dallas, TX, Estados Unidos de America
EUR 77,90
Cantidad disponible: 1 disponibles
Añadir al carritoHardcover. Condición: Good. Connecting readers with great books since 1972! Used textbooks may not include companion materials such as access codes, etc. May have some wear or writing/highlighting. We ship orders daily and Customer Service is our top priority!
Librería: THE SAINT BOOKSTORE, Southport, Reino Unido
EUR 66,40
Cantidad disponible: 1 disponibles
Añadir al carritoPaperback / softback. Condición: New. New copy - Usually dispatched within 4 working days.
Librería: PBShop.store UK, Fairford, GLOS, Reino Unido
EUR 76,78
Cantidad disponible: Más de 20 disponibles
Añadir al carritoPAP. Condición: New. New Book. Shipped from UK. Established seller since 2000.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 66,27
Cantidad disponible: 10 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: Books Puddle, New York, NY, Estados Unidos de America
EUR 80,48
Cantidad disponible: 3 disponibles
Añadir al carritoCondición: New. 1st edition NO-PA16APR2015-KAP.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 66,38
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 67,42
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: THE SAINT BOOKSTORE, Southport, Reino Unido
EUR 71,46
Cantidad disponible: 1 disponibles
Añadir al carritoPaperback / softback. Condición: New. New copy - Usually dispatched within 4 working days.
Librería: Books Puddle, New York, NY, Estados Unidos de America
EUR 83,32
Cantidad disponible: 3 disponibles
Añadir al carritoCondición: New. 1st edition NO-PA16APR2015-KAP.
Idioma: Inglés
Publicado por Chapman and Hall/CRC 2021-03-31, 2021
ISBN 10: 0367727072 ISBN 13: 9780367727079
Librería: Chiron Media, Wallingford, Reino Unido
EUR 69,92
Cantidad disponible: 10 disponibles
Añadir al carritoPaperback. Condición: New.